Journal: Investigational New Drugs
Article Title: Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma
doi: 10.1007/s10637-020-01040-y
Figure Lengend Snippet: Proliferation of non-malignant line of mesotheliocytes, as LP-9 and HMC7, after treatment with fludarabine (F-araA) and risedronic acid (RIS) Proliferation rate was measured 24, 48 and 72 h after either vehicle (dotted lines) or drug treatment (this is day = 0), as F-araA at 1 μM (A, B) or RIS at 10 μM (C, D) . Data represent mean ± SEM of two independent experiments, each performed in duplicate
Article Snippet: Gemcitabine was purchased from Chemodex, Fludarabine from AdooQ® Bioscience (Irvine, CA, USA), Risedronic Acid from LKT Laboratories (St Paul, MN USA), Cisplatin from AdipoGen® Life Science (Liestal, Switzerland).
Techniques: